| Quantity: | |
|---|---|
Ertugliflozin, is a medication for the treatment of type 2 diabetes.
The most common side effects include fungal infections of the vagina and other infections of the female reproductive system.
Ertugliflozin is a sodium/glucose cotransporter 2 (SGLT2) inhibitor and is in the class of drugs known as gliflozins.
In the United States, it was approved by the Food and Drug Administration for use as a monotherapy and as a fixed dose combination with either sitagliptin or with metformin. In the European Union, it was approved in March 2018, for use as a monotherapy or combination therapy. In September 2020, The New England Journal of Medicine reported that ertugliflozin was shown to be essentially non-inferior to placebo.
A combination with metformin is marketed as Segluromet and a combination with sitagliptin is marketed as Steglujan.
Function
Steglatro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications or in addition to other medicinal products for the treatment of diabetes.
Package
5.00kg/bag/drum, 5.00kg/bag ,2 bags/drum or according to customer’s requirements.
Ertugliflozin, is a medication for the treatment of type 2 diabetes.
The most common side effects include fungal infections of the vagina and other infections of the female reproductive system.
Ertugliflozin is a sodium/glucose cotransporter 2 (SGLT2) inhibitor and is in the class of drugs known as gliflozins.
In the United States, it was approved by the Food and Drug Administration for use as a monotherapy and as a fixed dose combination with either sitagliptin or with metformin. In the European Union, it was approved in March 2018, for use as a monotherapy or combination therapy. In September 2020, The New England Journal of Medicine reported that ertugliflozin was shown to be essentially non-inferior to placebo.
A combination with metformin is marketed as Segluromet and a combination with sitagliptin is marketed as Steglujan.
Function
Steglatro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications or in addition to other medicinal products for the treatment of diabetes.
Package
5.00kg/bag/drum, 5.00kg/bag ,2 bags/drum or according to customer’s requirements.
